More recently, they reported that targeting human cancer cells, including breast and prostate cancer cells with an RNAi procedure against CapG, significantly reduced the invasive and motile properties of both cells examined as well as cell aggregation [41]. This evidence concerns the gene CAPG and Familial prostate cancer.